November 2022 - Page 14 of 23

MondayNov 14, 2022 11:16 am

QualityStocksNewsBreaks – EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) Secures Full Funding for Core Expansion Project at FVB

EverGen (TSX.V: EVGN) (OTCQX: EVGIF), a leading Canadian renewable energy company and Canada’s renewable natural gas (“RNG”) infrastructure platform, appears to have a strong position to expedite growth as it remains committed to delivering on its ambitious goals for a more sustainable future. “EverGen Infrastructure has announced that its wholly owned subsidiary Fraser Valley Biogas Ltd. (‘FVB’) has signed a term sheet for a long-term RNG offtake agreement intended to replace the existing agreement as it approaches the end of the term. As a legal contract in which a buyer agrees to purchase a certain amount of the product at…

MondayNov 14, 2022 11:15 am

Vision Energy Corp. (VIHDD) Is ‘One to Watch’

Vision Energy in October 2022 announced it had completed conceptual layouts for its Green Energy Hub project in Vlissingen, the Netherlands The company in September 2022 announced its commitment to an additional 5.19 acres, expanding its Green Energy Hub project footprint to a total of 40.53 acres Vision Energy is on schedule to file for the remaining construction and environmental permits for its Green Energy Hub project by December 2022 Current hydrogen demand projections for northwest Europe outstrip scheduled production for the next five to 10 years Vision Energy (OTCQB: VIHDD) (“Vision Energy”) is a forward-looking energy company developing carbon…

MondayNov 14, 2022 10:30 am

Odyssey Health, Inc. (ODYY) Focuses on Medical Devices Market with US Patent Application on Breath-Propelled Intranasal Delivery Device

Odyssey filed for US and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device that effectively deposits concentrated drug deep into the nasal cavity for the treatment of CNS injury disease or disorder The application follows the successful completion of the second Cohort of Odyssey’s Phase I MAD clinical trial, which saw the effective use of the device and a proven safety profile for the company’s concussion pharmaceutical treatment Michael Redmond, the company’s CEO, has expressed the company’s pleasure in the functionality of the device, citing how it provides a significant opportunity and advantage for the treatment of…

MondayNov 14, 2022 9:45 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Maintains Focus on Advancing Clinical Development Program for Lead Drug Candidate, Berubicin

In June 2020, CNS’ lead drug candidate, Berubicin, received Orphan Drug designation from the FDA. In June 2021, it received Fast Track designation following positive results from an extensive clinical study that saw 44% of the patients post a clinical response, with one Durable Complete Response With GBM having a survival rate of only 6.8% and an average length of survival of only eight months, Berubicin is showing tremendous potential, and CNS is leading the charge to find a potential treatment option for the disease CNS’ management is optimistic about its lead drug candidate and continues to explore the potential…

MondayNov 14, 2022 9:00 am

Company Profile: Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM)

Eloro Resources Ltd. Owns a 98% interest in Minera Tupiza with an option to acquire 99% interest in a neighboring highly sought after, royalty-free property in southern Bolivia Eloro has an option to acquire a 99% interest in the 9 square km, highly prospective Iska Iska Property, which hosts a major silver-tin polymetallic porphyry-epithermal complex located 4,000m above sea level Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM), a publicly traded exploration and mine development company, established in 1985 with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec. Polymetallic Project in Bolivia Bolivia’s modern mining…

FridayNov 11, 2022 2:11 pm

QualityStocksNewsBreaks – CubCrafters Inc. Stands Distinct in Manufacturing Four Categories of Airplanes

CubCrafters, a best-in-class backcountry aircraft producer, turned heads when it announced in July that it will make a public offering to raise investment capital through the sale of preferred stock. “Within the first 48 hours of its announcement, CubCrafters received $5 million in reservations for 1 million planned shares, which has grown beyond $20 million in reservations in the subsequent weeks as the company awaits qualification for its listing from the U.S. Securities and Exchange Commission (‘SEC’). The reservations for the company’s shares have taken off, rising closer and closer to its initial goal for the public offering,” a recent…

FridayNov 11, 2022 12:00 pm

QualityStocksNewsBreaks – GeoSolar Technologies Inc.’s SmartGreen System Featured in Home BUILDER Article

GeoSolar Technologies was featured in a recent article published by Home BUILDER Magazine. The piece describes Hurricane Ian’s tumultuous debut into southeast Florida on Sept. 23, 2022, where it knocked out power for millions of residents, nearly destroyed cities such as Naples and Fort Myers and left an estimated $50 billion of damage in its path. On the bright side of the devastating event in the Sunshine State, the publication describes the 2,000-home master-planned community of Babcock Ranch, which is less than 20 kilometers from Fort Myers, that road out the Cat 4 hurricane without loss of power and with…

FridayNov 11, 2022 11:51 am

QualityStocksNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Milestone in IND-Enabling Study of Time-Released Ketamine Formulation

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced initial dosing in its IND-enabling study of SP-26, its novel time-released, topical formulation of ketamine. According to the update, the objective of this safety evaluation study, conducted by Experimur (a Frontage Company), is to evaluate the SP-26 compound to establish a maximum tolerated dose. The new drug is intended to treat fibromyalgia, a chronic condition causing widespread musculoskeletal pain accompanied by fatigue, sleep problems and memory issues. “Our team is excited about this milestone in our collaboration with our joint venture…

FridayNov 11, 2022 11:45 am

QualityStocksNewsBreaks – Coyuchi Inc.’s Pismo Organic Throw Makes List of Top Gifts for ‘Impossible Parents’

Coyuchi, the gold standard in sustainable luxury home goods, was featured in a recent Yahoo! Life article. The piece, written by Loren Cecil and Jonathan Zavaleta, shares a list of “The 35 Best Gifts for Impossible Parents Who Say They Already Have Everything They Need.” Coyuchi’s Pismo Organic Throw is included in the array of excellent gift options for seemingly hard-to-please folks. “Every couch needs a good throw to get extra cozy for naps and movie nights. It feels like a very dad thing to fall asleep on the couch during a movie, so he may be the one who…

FridayNov 11, 2022 11:38 am

QualityStocksNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q3 2022 Financial Report

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, is reporting its financial and operational updates for the third quarter; the quarter ended on Sept. 30, 2022. Included in the report is the fact that the company’s AIMI(TM) platform technology, which is used for diagnosing heart attacks, has been submitted to the U.S Food and Drug Administration (“FDA”) for clearance and the company is on track for initial FDA submission of its AIMIGo(TM) device in the next quarter. Other highlights include that the company broadened…

Site Search

Company Search

Month: November 2022